Bayer’s Antidumping Gambit and Supreme Court Win Create a Rally — but a Missouri Judge Will Decide Its Fate

Bayer stock surges after Supreme Court limits Roundup lawsuits and it files antidumping petition; July 9 court ruling on settlement is key.

Bayer is mounting a two-front campaign to reshape its legal and competitive landscape. Just days after the U.S. Supreme Court dealt a devastating blow to state-level Roundup litigation, the Leverkusen group’s crop science subsidiary filed a petition with the U.S. Department of Commerce demanding antidumping duties on Chinese glyphosate imports. The move has helped propel the stock to within striking distance of its 52-week high, but a pivotal court hearing in St. Louis on July 9 will determine whether the rally has legs.

The antidumping petition targets a market where China currently supplies roughly 99% of the glyphosate used in the United States. Bayer argues that underpriced Chinese imports are threatening its domestic production base. The U.S. International Trade Commission will now investigate whether those imports distort the market. Resistance is already building: farm groups such as the National Association of Wheat Growers warn that additional levies could add $1 billion to American farmers’ annual costs. The political timing is delicate — President Trump just suspended tariffs on Moroccan fertilizer to protect food supply chains, underscoring the sensitivity of any move that raises input prices for agriculture.

The trade offensive follows a landmark legal victory. On June 25, the Supreme Court ruled that federal labeling requirements for glyphosate preempt state-law claims over missing cancer warnings. The decision effectively extinguishes the vast majority of the roughly 65,000 pending Roundup lawsuits and gives Bayer the leverage it needs to finalize a $7.25 billion settlement hammered out in February with Missouri plaintiffs’ attorneys. That deal, which still requires a judge’s approval, is designed to cap future liabilities and end nearly a decade of litigation over the herbicide.

All eyes are now on the St. Louis courtroom. If the judge signs off on July 9, Bayer will have eliminated the bulk of its legal overhang in one stroke. But plaintiffs’ lawyers have already voiced sharp criticism of the terms, and a rejection would instantly reopen the floodgates of litigation — even after the Supreme Court ruling, which does not address claims based on design defects or negligence. A failure would likely wipe out much of the stock’s recent gains.

Investors have so far treated the combination of judicial relief and aggressive trade policy as a green light. The stock climbed nearly 5% in Wednesday’s session to €48.15, leaving it just 3% below its 52-week peak of €49.93. Over the past seven days the rally has reached 24.87%, and over 30 days the gain stands at 36.83%. The rapid advance has pushed the relative strength index to 79.8 — deep into overbought territory — signaling that the technical picture is stretched.

Behind the rally lies a balance sheet under pressure. Bayer reported a negative free cash flow of €2.32 billion in the first quarter of 2026, and net debt swelled to €32.5 billion by the end of March. Chief Financial Officer Wolfgang Nickl has budgeted roughly €5 billion for legal costs this year alone. The settlement, if approved, would provide a measure of closure, but it does not solve the underlying cash drain from declining pharmaceutical revenues and still-high leverage.

The pharma division offers both hope and risk. The blood thinner Asundexian has collected accelerated review status from the U.S. Food and Drug Administration, Chinese regulators, and the European Medicines Agency after a pivotal study showed a 26% reduction in stroke risk with no increase in bleeding compared with placebo. Bayer aims to return the pharma business to mid-single-digit growth from 2027 and push the operating margin toward 30% by 2030. But Asundexian previously failed a major trial for atrial fibrillation in 2023, and the company must also compensate for shrinking sales of its blockbuster Xarelto, which fell by a third last year to $2.6 billion.

The next two events will set the tone for the rest of 2026. On July 9, the Missouri court decides whether to bless the settlement. On August 3, Bayer reports second-quarter earnings, with the market focused on free cash flow and evidence that the operational turnaround is taking hold. If both land in Bayer’s favor, a fundamental revaluation could begin. If either falters, the stock — already showing signs of exhaustion — will have little to fall back on.